Literature DB >> 20634296

Comparison of different measures of urinary protein excretion for prediction of renal events.

Hiddo J Lambers Heerspink1, Ron T Gansevoort, Barry M Brenner, Mark E Cooper, Hans Henrik Parving, Shahnaz Shahinfar, Dick de Zeeuw.   

Abstract

There are many methods to screen for abnormal amounts of proteinuria to identify patients at risk for progression of renal disease, but which method best predicts renal risk is unknown. Here, we analyzed a subset of 701 patients with type 2 diabetes and nephropathy participating in the Reduction of Endpoints in Non Insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) trial to compare the ability of urinary protein excretion (UPE) and urinary albumin excretion (UAE) from a 24-hour urine collection and urinary albumin concentration (UAC) and the albumin:creatinine ratio (ACR) from a first-morning void in predicting renal events. The primary outcome measure was the time to a doubling of serum creatinine or end-stage renal disease. During follow-up, 202 events occurred. The hazard ratios for the risk of a renal outcome (95% CIs) associated with 1-SD increment in the log-transformed measures were 3.16 (2.60 to 3.86) for UAE, 3.02 (2.53 to 3.62) for UPE, 3.23 (2.67 to 3.91) for UAC, and 4.36 (3.50 to 5.45) for ACR. The area under the ROC curve was significantly higher for ACR compared with the other measures. In conclusion, measurement of the albumin:creatinine ratio in a first-morning void is the superior method to predict renal events in patients with type 2 diabetes and nephropathy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20634296      PMCID: PMC2938598          DOI: 10.1681/ASN.2010010063

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  19 in total

1.  Diurnal variations of glomerular filtration rate and albuminuria in diabetic nephropathy.

Authors:  Henrik P Hansen; Peter Hovind; Berit R Jensen; Hans-Henrik Parving
Journal:  Kidney Int       Date:  2002-01       Impact factor: 10.612

2.  Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group.

Authors:  D F Easton; J Peto; A G Babiker
Journal:  Stat Med       Date:  1991-07       Impact factor: 2.373

3.  Practical aspects of measuring microalbuminuria in diabetic patients.

Authors:  G Jermendy; K Farkas; J Nádas; A Daróczy; E Péterfai
Journal:  Diabetes Nutr Metab       Date:  2001-08

4.  Evaluation of measures of urinary albumin excretion.

Authors:  Ronald T Gansevoort; Jacoline Brinkman; Stephan J L Bakker; Paul E De Jong; Dick de Zeeuw
Journal:  Am J Epidemiol       Date:  2006-08-25       Impact factor: 4.897

5.  Management of hypertension and screening of renal complications by GPs in diabetic type 2 patients (France--2001).

Authors:  F Fagnani; T Souchet; D Labed; S Gaugris; T Hannedouche; A Grimaldi
Journal:  Diabetes Metab       Date:  2003-02       Impact factor: 6.041

6.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes.

Authors:  P Ruggenenti; F Gaspari; A Perna; G Remuzzi
Journal:  BMJ       Date:  1998-02-14

8.  Diabetes services in the UK: fourth national survey; are we meeting NSF standards and NICE guidelines?

Authors:  J A Edge; P G F Swift; W Anderson; B Turner
Journal:  Arch Dis Child       Date:  2005-06-07       Impact factor: 3.791

9.  The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).

Authors:  B M Brenner; M E Cooper; D de Zeeuw; J P Grunfeld; W F Keane; K Kurokawa; J B McGill; W E Mitch; H H Parving; G Remuzzi; A B Ribeiro; M D Schluchter; D Snavely; Z Zhang; R Simpson; D Ramjit; S Shahinfar
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2000-12       Impact factor: 1.636

10.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Kidney Int       Date:  2004-06       Impact factor: 10.612

View more
  46 in total

Review 1.  Established and emerging markers of kidney function.

Authors:  Michael A Ferguson; Sushrut S Waikar
Journal:  Clin Chem       Date:  2012-02-06       Impact factor: 8.327

2.  Assessment of kidney function: UACR--two risk markers or a 24 h collection in a minute?

Authors:  Peter Rossing
Journal:  Nat Rev Nephrol       Date:  2012-05-08       Impact factor: 28.314

3.  An Age-Calibrated Definition of Chronic Kidney Disease: Rationale and Benefits.

Authors:  Pierre Delanaye; Richard J Glassock; Hans Pottel; Andrew D Rule
Journal:  Clin Biochem Rev       Date:  2016-02

4.  Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.

Authors:  Tobias F Kröpelin; Dick de Zeeuw; Dennis L Andress; Maarten J Bijlsma; Frederik Persson; Hans-Henrik Parving; Hiddo J Lambers Heerspink
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-07       Impact factor: 8.237

Review 5.  Measurement of renal function in patients with chronic kidney disease.

Authors:  Euan A Sandilands; Neeraj Dhaun; James W Dear; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

6.  Influence of urine creatinine on the relationship between the albumin-to-creatinine ratio and cardiovascular events.

Authors:  Caitlin E Carter; Ronald T Gansevoort; Lieneke Scheven; Hiddo J Lambers Heerspink; Michael G Shlipak; Paul E de Jong; Joachim H Ix
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-01       Impact factor: 8.237

7.  Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.

Authors:  David B Sacks; Mark Arnold; George L Bakris; David E Bruns; Andrea Rita Horvath; M Sue Kirkman; Ake Lernmark; Boyd E Metzger; David M Nathan
Journal:  Diabetes Care       Date:  2011-06       Impact factor: 19.112

8.  Comparison of associations of urine protein-creatinine ratio versus albumin-creatinine ratio with complications of CKD: a cross-sectional analysis.

Authors:  Herrick Fisher; Chi-Yuan Hsu; Eric Vittinghoff; Feng Lin; Nisha Bansal
Journal:  Am J Kidney Dis       Date:  2013-09-14       Impact factor: 8.860

9.  Albuminuria prevalence in first morning void compared with previous random urine from adults in the National Health and Nutrition Examination Survey, 2009-2010.

Authors:  Sharon H Saydah; Meda E Pavkov; Cindy Zhang; David A Lacher; Mark S Eberhardt; Nilka Rios Burrows; Andrew S Narva; Paul W Eggers; Desmond E Williams
Journal:  Clin Chem       Date:  2013-01-11       Impact factor: 8.327

10.  Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio.

Authors:  William Herrington; Nicola Illingworth; Natalie Staplin; Aishwarya Kumar; Ben Storey; Renata Hrusecka; Parminder Judge; Maria Mahmood; Sarah Parish; Martin Landray; Richard Haynes; Colin Baigent; Michael Hill; Sarah Clark
Journal:  Clin J Am Soc Nephrol       Date:  2016-09-21       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.